Premium
Non‐histaminergic angioedema: focus on bradykinin‐mediated angioedema
Author(s) -
Busse P. J.,
Buckland M. S.
Publication year - 2013
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12019
Subject(s) - angioedema , histaminergic , bradykinin , medicine , histamine , dermatology , receptor
Summary Angioedema is a result of increased vascular permeability, with subsequent extravasation of intravascular fluid into the surrounding tissues. Angioedema may be mediated by histamine, bradykinin or other mediators. Histaminergic angioedema generally presents with urticaria and/or pruritus and will respond to conventional treatment with antihistamines, corticosteroids or epinephrine. Bradykinin‐mediated angioedema, which includes hereditary angioedema ( HAE types I , II and III ), acquired C 1‐ INH deficiency, and angiotensin‐converting enzyme inhibitor‐induced angioedema does not typically present with urticaria/weals and does not respond to conventional agents such as antihistamines or corticosteroids. In recent years, several agents that prevent the generation or activity of bradykinin have been developed for the treatment of HAE types I and II and are also being evaluated in other types of bradykinin‐mediated angioedema. These agents have the potential to improve outcomes for patients with different forms of bradykinin‐mediated angioedema.